Fundz

Mentari Therapeutics Completes Merger with InMed Pharmaceuticals

PRIVATENov 09, 2026

Acquiring Company

Mentari Therapeutics

Acquired Company

InMed Pharmaceuticals

DelawareVancouverBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaHealthcare

Description

On November 9, 2026, Mentari Therapeutics, Inc. announced the completion of its merger with InMed Pharmaceuticals Inc. This significant move aims to enhance Mentari's portfolio and expertise in cannabinoid-based therapies. The merger is expected to bolster the combined company's capabilities in drug development and innovation. Both companies are committed to advancing therapeutic options for patients.

Who to call at Mentari Therapeutics, and when

When Mentari Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Mentari Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Mentari Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Mentari Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Mentari Therapeutics

Location

Delaware, United States

About

Mentari Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies. The company is dedicated to researching and advancing treatment options in the healthcare market. With a commitment to innovation, Mentari aims to improve the quality of life for patients. Their expertise lies in the intersection of drug development and therapeutic interventions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Mentari Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Mentari Therapeutics's next move

Learn about Strategic plan

Frequently asked

Who acquired InMed Pharmaceuticals?

InMed Pharmaceuticals was acquired by Mentari Therapeutics, based in Delaware. The deal was reported on November 9, 2026. Mentari Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies. The company is dedicated to researching and advancing treatment options in the healthcare market. Mentari Therapeutics is privately held and operates in Biotechnology.

When did Mentari Therapeutics acquire InMed Pharmaceuticals?

Mentari Therapeutics's acquisition of InMed Pharmaceuticals was reported on November 9, 2026. On November 9, 2026, Mentari Therapeutics, Inc. announced the completion of its merger with InMed Pharmaceuticals Inc. This significant move aims to enhance Mentari's portfolio and expertise in cannabinoid-based therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does InMed Pharmaceuticals do?

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. It is publicly traded (INM), operating in Healthcare, and is based in Vancouver.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.